Transgender dermatologic literature is limited; no data exists on the prevalence and risk of psoriasis and PsA in the transgender/gender-diverse populations. Ms Julia Gao (Fenway Health, MA, USA) and colleagues conducted a retrospective comparative cohort study with electronic health records of transgender/gender-diverse adults on masculinising or feminising hormone therapy and cisgender adults seen at Fenway Health between 1 August 2014 and 1 August 2020.
The sample of over 46,000 persons included approximately 1,400 adults on feminising hormone therapy, almost 1,600 adults on masculinising hormone therapy, over 25,000 cisgender men, approximately 17,000 cisgender women, 535 transmasculine adults not on gender-affirming hormone therapy, and 447 transfeminine adults not on gender-affirming hormone therapy. Of the cisgender adults, most cisgender men and over 11,000 cisgender women were not receiving exogenous hormone therapy such as testosterone replacement, hormonal birth control, or menopausal hormone replacement therapy.
Results indicated that patients on feminising hormone therapy were less likely to have psoriasis compared with all cisgender men (OR 0.59; 95% CI 0.33–0.96; P=0.0339) and compared with cisgender men not receiving exogenous hormone therapy (OR 0.59; 95% CI 0.34–0.98; P=0.0388). Patients on masculinising hormone therapy were not at a significantly higher risk of having psoriasis compared with all cisgender women (OR 1.04; 95% CI 0.59–1.72).
No significant difference in the risk of PsA was found between patients on feminising hormone therapy compared with all cisgender men (OR 1.35; 95% CI 0.15–5.74) nor between patients on masculinising hormone therapy compared with all cisgender women (OR 1.35; 95% CI 0.15–5.74).
Transgender/gender-diverse adults on masculinising hormone therapy had a similar risk of psoriasis or PsA compared with cisgender women. In contrast, adults on feminising hormone therapy were significantly less likely to have psoriasis, but not PsA, compared with cisgender men. These findings indicate that transgender adults on gender-affirming hormone therapy are not at an increased risk of developing psoriasis or PsA.
- Gao JL. Psoriasis and Psoriatic Arthritis in Transgender Patients on Hormone Therapy: A Retrospective Comparative Cohort Study. Abstract O4, 6th World Psoriasis & Psoriatic Arthritis Conference, 30 June–3 July 2021.
Copyright ©2021 Medicom Medical Publishers
Posted on
site created by:
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com